Compare DuPont de Nemours Inc (DD) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Humana Inc — how do they compare? DuPont de Nemours Inc trades at $130 (market cap $17.89B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 2.6× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays the higher dividend (1.81%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Humana Inc for 51 Days on average.
| DD | HUM | |
|---|---|---|
Market Cap | $17.89B | $46.49B |
Volume | 816,409 | 2,567,704 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $431.03 |
52-Week Low | $92.49 | $163.67 |
Typical Hold Time | 89 Days | 51 Days |
Enterprise Value | $19.28B | $53.84B |
Dividend Yield | 1.81% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, up 1.07% with neutral technical signals. The company shows mixed fundamentals with strong recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst consensus is bullish with 59% buy ratings, though the $95 consensus price target suggests downside risk. Recent developments include new product launches in sustainable materials and digital tools, alongside ongoing legal settlements related to PFAS contamination.
Outlook remains cautious due to revenue contraction and margin pressure, offset by innovation in high-growth sectors like healthcare and water technologies. Key risks include legal liabilities from PFAS lawsuits and volatile cash flows, while institutional sentiment appears divided with recent stake reductions by several funds.
Humana (HUM) trades at $387.12, down 2.37% today, with a bullish technical outlook supported by moving averages and strong institutional interest. The company shows steady revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent analyst upgrades and a $460.74 consensus price target suggest upside potential, while Medicare Advantage plan changes and fiduciary scrutiny present near-term headwinds.
The stock offers value with a low P/S ratio of 0.32x and consistent earnings beats, but faces margin pressure and regulatory risks. Institutional accumulation and positive technicals support a constructive outlook, though investors should monitor enrollment trends and cost management execution for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
